EY Q1 Pharma M&A Report sees ADCs taking center stage

3 May 2023

Total investment in biopharma M&A in the first quarter of 2023 was over four times the equivalent value for first quarter 2022, including the first megadeal since December 2020 with Pfizer (NYSE: PFE) paying $43 billion to acquire Seagen (Nasdaq: SGEN).

However, despite these high headline numbers, findings reveal the global biopharma industry is still playing it safe – with overall activity down 22% from first-quarter 2022.

EY’s latest Life Sciences Quarterly M&A Update (1Q’23) explores the deal value and volume trends over the quarter, as well as predictions for the remainder for 2023. Notably, as the beginning of the year has been characterized by an unsettled global climate, a rebound later in 2023 looks likely, with a focus on new modalities such as antibody-drug conjugates (ADCs).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK